DHEA Hormone

## What it is Dehydroepiandrosterone (DHEA) is a 19-carbon steroid produced primarily by the adrenal cortex (zona reticularis) and in smaller amounts by the gonads and brain. Together with its sulfate ester DHEA-S, it is the most abundant circulating steroid hormone in humans, with serum levels exceeding those of testosterone, estradiol, and cortisol. DHEA was first isolated in 1934 by Adolf Butenandt; its physiological role remained obscure until the 1980s, when the age-related decline pattern brought it to attention as a candidate longevity intervention. Endogenous DHEA-S concentrations follow a striking trajectory. Levels are high in fetal life, drop sharply at birth, rise again during adrenarche around age 6 to 8, peak in the third decade (around 1500 to 4000 ng/mL in young adults), and decline progressively thereafter. By age 70, DHEA-S levels are typically 20 to 30% of young-adult peak. This 'adrenopause' pattern motivated the hypothesis that replacement might restore aspects of younger-adult physiology. The regulatory shape of DHEA is internationally divided. In the US, the Dietary Supplement Health and Education Act (DSHEA, 1994) classifies DHEA as a dietary supplement, available without prescription at any dose. In the EU, UK, Canada, and Australia, DHEA is regulated as a prescription medication or scheduled substance. The transatlantic split is one of the most consequential supplement-versus-Rx differences in the modern formulary: a US user can buy 50 mg daily at any vitamin shop, while a UK user requires a prescription and the indication is narrow. FDA-approved DHEA products in the US are limited to Intrarosa (prasterone vaginal insert, 6.5 mg), approved in 2016 for moderate-to-severe dyspareunia in postmenopausal vulvovaginal atrophy. All other oral DHEA in the US is sold as a dietary supplement without FDA evaluation of efficacy. ## Mechanism of action DHEA is a steroid prohormone with weak direct activity at sex hormone receptors. Its primary biological role is as a precursor: tissue-specific intracellular enzymes convert DHEA into androstenedione, testosterone, dihydrotestosterone, and estrogens (estrone, estradiol). The conversion pattern depends on which enzymes the target tissue expresses, which produces tissue-specific androgenic or estrogenic effects from the same circulating substrate. This mechanism is termed 'intracrinology' and was formalized by Fernand Labrie in the 1990s. In adrenal-insufficient women, DHEA replacement raises circulating testosterone and estradiol toward normal range, restoring androgen tone that the dysfunctional adrenals cannot produce. In healthy older adults, DHEA supplementation produces smaller and more variable changes in downstream sex steroids, with women showing larger relative increases than men because women have lower baseline endogenous androgen production. DHEA also has direct effects independent of conversion to sex steroids. It is a non-competitive sigma-1 receptor agonist, modulates GABA-A signaling, and affects glucocorticoid receptor activity. These mechanisms underlie proposed mood and cognitive effects but are mechanistically less well-mapped than the prohormone pathway. Pharmacokinetics: oral DHEA is rapidly absorbed (peak 30 to 60 minutes), substantially first-pass sulfated to DHEA-S, and the half-life of DHEA-S is roughly 12 to 24 hours. Daily morning dosing is the standard approach to mimic the diurnal endogenous pattern. ## Evidence base by outcome ### Adrenal insufficiency in women B-tier. The strongest indication. Multiple trials in women with primary or secondary adrenal insufficiency report improvements in well-being, sexual function, and mood when DHEA is added to glucocorticoid replacement. Arlt 1999 (NEJM) was the seminal trial. Effects in men with adrenal insufficiency are smaller because endogenous testosterone production is intact. ### Vaginal atrophy and dyspareunia A-tier (for the FDA-indicated 6.5 mg vaginal insert). Three Phase 3 trials supported the Intrarosa approval (2016). Effects on dyspareunia, vaginal pH, and tissue maturation are robust. Oral DHEA effects on this endpoint are smaller and less well-characterized. ### Bone mineral density B-tier in older women, C-tier in older men. Meta-analyses in postmenopausal women report small BMD improvements at 50 to 100 mg daily for 6 to 24 months. Effect sizes are smaller than dedicated bone agents (bisphosphonates, denosumab). Trials in men have been mixed. ### Body composition C-tier. Villareal 2004 (n=56 older adults, 6 months) reported small fat-mass reduction and lean-mass gain at 50 mg daily. Other trials have been mixed. The pattern in well-designed trials is small effects with substantial inter-individual variability. ### Cognitive function and mood C-tier. Meta-analyses across 12+ trials in older adults are largely null on cognitive endpoints. Mood improvements are reported in some trials, particularly in adrenal insufficiency and depression contexts, but the signal is small in healthy older adults. Evidence does not support DHEA as a cognitive enhancer. ### Sexual function in older women B-tier on libido endpoints in adrenal-insufficient women. C-tier in healthy postmenopausal women. The vaginal preparation (Intrarosa) has stronger local-tissue evidence than oral DHEA has on systemic libido endpoints. ### IVF and fertility C-tier. Small trials in women with diminished ovarian reserve have reported improved oocyte yield and pregnancy rates. The evidence base is heterogeneous and dominated by single-center studies; larger meta-analyses have been mixed. DHEA is widely used in fertility clinics despite the soft evidence base. ### Skin and aging biomarkers C to D-tier. Topical and oral DHEA has been reported to improve skin thickness and hydration in small trials. Systemic anti-aging effects on biomarkers (telomere length, methylation age) have not been demonstrated. ### Cardiovascular outcomes D-tier. No completed long-term trials power CV endpoints. Observational data on DHEA-S and cardiovascular mortality have been mixed. ### Lifespan and healthspan D-tier. No human trial has tested DHEA against hard longevity endpoints. The MASS pilot at Saint Louis University ran small composite endpoint trials in older adults without finding meaningful frailty benefit. The geroprotective hypothesis remains preliminary. ## Dosage and administration Dosing varies by indication and sex. For adrenal insufficiency in women, 25 to 50 mg daily is the typical target. For postmenopausal women without adrenal insufficiency, doses range from 10 to 50 mg daily depending on goals. For men, doses above 25 mg daily are rarely needed and can produce androgenic side effects. The Intrarosa vaginal insert is 6.5 mg daily. Morning dosing mimics the endogenous diurnal pattern. Take with food to improve absorption. Quality varies enormously across over-the-counter US supplements; ConsumerLab and USP-verified products are more reliable than untested supplement-store products. No cycling is part of standard protocol. Dose-response is mostly characterized for short-term endpoints; long-term dosing is empirical. Monitoring: DHEA-S levels at baseline and 3 to 6 months after initiation; total testosterone and estradiol if androgenic or estrogenic side effects develop. Target DHEA-S levels in the upper range for chronological age, not necessarily youth-range. ## Side effects and safety Side effect profile is dominated by androgenic effects in women and estrogenic effects in men. Acne, oily skin, increased facial hair (hirsutism), and voice deepening can develop in women on doses above 25 to 50 mg daily, particularly with prolonged use. Men can develop gynecomastia from estrogen-pathway conversion at higher doses, more common in users with higher aromatase activity. Mood and sleep changes occur in a minority of users. Some report improved energy and well-being; others report irritability or insomnia. Lipid changes (modest HDL reduction in women) have been reported. The clinical significance is unclear. Prostate effects are theoretically a concern given downstream conversion to testosterone and DHT. The available trial data have not shown PSA elevation or prostate symptom worsening at typical doses, but men with active prostate cancer or untreated severe BPH should not use DHEA. Hormone-sensitive cancers (breast, ovarian, prostate) are conventional contraindications given the conversion pathways. DHEA is WADA-banned in competitive sport. Athletes face urine-testing detection risk via metabolite ratios. Drug interactions are limited. Anticoagulant interactions are reported in a few case studies. Insulin requirements may change in diabetic users due to small effects on insulin sensitivity. Pregnancy: contraindicated. ## Stack interactions and timing DHEA pairs reasonably with vitamin D, omega-3, and standard nutritional supplements. The combinatorial evidence with other hormones (testosterone, estrogen) is essentially absent in trials; clinical practice in HRT contexts often combines DHEA with other replacement therapies but the additive benefit is empirical. In fertility protocols, DHEA is often combined with CoQ10 (ubiquinol) for oocyte mitochondrial quality, with the combination supported by small trials in diminished ovarian reserve. In adrenal insufficiency replacement, DHEA is added to existing glucocorticoid (hydrocortisone) and mineralocorticoid (fludrocortisone) replacement. ## Practical notes Quality control is the dominant practical issue for US users buying OTC. A 2007 study (Parasrampuria) found that DHEA content in OTC products varied from 0% to 150% of the labeled dose. Choose third-party-tested brands (ConsumerLab, USP, NSF). Most benefits accumulate over weeks to months. Allow 8 to 12 weeks at a stable dose before judging response. Track DHEA-S levels rather than DHEA itself, since DHEA is rapidly converted and produces a less stable readout. The honest framing for the use case: in confirmed adrenal insufficiency, DHEA replacement has moderate evidence and is reasonable. For vaginal atrophy, the FDA-approved Intrarosa product has strong indication-specific evidence. For broader anti-aging or longevity claims in healthy older adults, the evidence base is preliminary, and the androgenic/estrogenic side effects from supraphysiological dosing are real. Anyone using OTC DHEA in the US for longevity or performance is making a bet on indirect mechanism evidence rather than completed outcome trials.